MONTE ROSA THERAPEUTICS INC (GLUE)
Sector: Health Care
2026 Annual Meeting Analysis
MONTE ROSA THERAPEUTICS INC · Meeting: June 11, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class II Directors
Dr. Schiff has served since 2020 and brings strong venture capital and life sciences board experience; the stock's 3-year return of +303.4% outperforms the XBI — SPDR S&P Biotech ETF by approximately +245.5 percentage points, far exceeding the 65-point threshold required to trigger an against vote, so no TSR concern applies; no overboarding, attendance, independence, or familial relationship issues were identified.
Dr. Leo has served since 2020 and contributes deep healthcare investment and medical expertise; the same strong TSR outperformance versus the XBI — SPDR S&P Biotech ETF that clears the policy threshold applies equally to his tenure; he holds no public company board seats (only private company directorships), so overboarding is not a concern, and no other policy triggers apply.
Dr. Manning joined in July 2023 and brings 30 years of pharmaceutical drug discovery experience; because he joined less than 36 months ago and his tenure covers less than the full 3-year TSR measurement window, the strong outperformance versus the XBI — SPDR S&P Biotech ETF is in any case a positive backdrop; no overboarding, attendance, independence, or familial relationship issues were identified.
All three Class II nominees are recommended FOR. Monte Rosa's stock has delivered a 3-year return of approximately +303%, outperforming the XBI — SPDR S&P Biotech ETF by roughly +245 percentage points — well above the 65-point threshold that would be needed to trigger an against vote. Each nominee has relevant industry credentials, all directors met the 75% attendance threshold, all are classified as independent, and no familial relationships or overboarding concerns exist.
Say on Pay
✓ FORCEO
Markus Warmuth, M.D.
Total Comp
$5,032,728
Prior Support
N/A
Monte Rosa is an emerging growth company and is not required to hold an advisory say-on-pay vote; no such proposal appears on the 2026 ballot, so this analysis is based on the compensation disclosures provided. The CEO received total compensation of approximately $5.03 million in 2025, with roughly 87% in variable pay (stock awards, stock options, and performance bonus) and only 13% in base salary — a pay mix that comfortably exceeds the policy's requirement that at least 50-60% of pay be performance-based. The company has a Dodd-Frank-compliant clawback policy adopted in September 2023, and the stock's exceptional 3-year return of +303% versus the XBI — SPDR S&P Biotech ETF strongly supports the view that incentive pay has been aligned with shareholder outcomes.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
N/A
Audit Fees
$1,085,291
Non-Audit Fees
$1,895
Non-audit fees of $1,895 represent less than 0.2% of audit fees of $1,085,291, far below the 50% threshold that would raise independence concerns; Deloitte is a Big 4 firm appropriate for a $1.5 billion market cap company; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire and the policy requires a FOR vote in that circumstance; no material restatements were identified.
Overall Assessment
The 2026 Monte Rosa Therapeutics annual meeting contains two formal proposals: election of three Class II directors and ratification of Deloitte as auditor. Both proposals pass all policy screens and receive a FOR determination — the director nominees have relevant credentials and the stock has dramatically outperformed the XBI — SPDR S&P Biotech ETF over three years, while Deloitte's non-audit fees are negligible and no tenure or restatement concerns apply.